Effects of fluvastatin treatment on lipid profile, C-reactive protein trend, and renal function in dyslipidemic patients with chronic renal failure

• Published in: Advances in therapy 2005-11, Vol.22 (6), p.601-612
• Main Authors: Di Lullo, L, Addesse, R, Comegna, C, Firmi, G, Galderisi, C, Iannacci, G R, Polito, P
• Format: Article
• Language: English
• Subjects: Anticholesteremic Agents - administration & dosage; Anticholesteremic Agents - therapeutic use; C-Reactive Protein - analysis; Creatinine - blood; Delayed-Action Preparations; Dyslipidemias - complications; Dyslipidemias - drug therapy; Dyslipidemias - physiopathology; Fatty Acids, Monounsaturated - administration & dosage; Fatty Acids, Monounsaturated - therapeutic use; Female; Health technology assessment; Humans; Indoles - administration & dosage; Indoles - therapeutic use; Kidney Failure, Chronic - complications; Kidney Failure, Chronic - drug therapy; Kidney Function Tests; Lipids - blood; Male; Middle Aged; Prospective Studies
• ISSN: 0741-238X; 1865-8652
• DOI: 10.1007/BF02849954

The purpose of this trial was to evaluate the effects of fluvastatin on the lipid pro-file and on renal function, as measured by creatinine clearance, in dyslipidemic patients with chronic renal failure. In this 8-month prospective, open-label, randomized, parallel-group trial, 130 patients (70 men and 60 women), after a 2-month washout period following previous lipid-lowering treatments, were randomly assigned to fluvastatin XL 80 mg given once daily (80 patients) or to standard treatment (50 patients). Mean total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglyceride values after 3 and 6 months of treatment with fluvastatin showed statistically significant improvement compared with standard treatment. Improved renal function, as measured by creatinine clearance, was observed at the end of the 6-month treatment period in approximately 65% of patients treated with fluvastatin. The increase in creatinine clearance consistently reached 10% to 15% of baseline values. A statistically significant reduction in C-reactive protein (CRP) over baseline values was observed in approximately 75% of patients treated with fluvastatin. Furthermore, mean values of CRP for the fluvastatin standard treatment groups, respectively, were 6.78 and 10.19 at 3 months and 4.47 and 11 at 6 months. Both treatments were well tolerated. No major adverse events were noted. Results of this study suggest that fluvastatin treatment in patients with chronic renal failure is effective in improving the lipid profile, and it demonstrates good safety and tolerability. Furthermore, fluvastatin may contribute to improved nephroprotection in this patient population.